Luís Moita e il tribunale permanente dei popoli

L’ipotesi di lavoro di questo contributo è quella di raccontare la presenza e partecipazione di Luís Moita alla vita del Tribunale Permanente dei Popoli (TPP) come documentazione di un percorso e di un metodo di ricerca di una persona che ha coniugato, in modo esemplare, un’identità di militante (nel senso più pieno del termine) e di intellettuale lucido ed insieme trasversale a molte discipline. Pur nel cambiare ovvio e radicale dei contesti geopolitici, l’originalità e la produttività del suo essere presente nella storia sono di una attualità politica e culturale che non ha scadenza. Soprattutto per coloro che pensano al vivere sociale come un perenne, obbligatorio, liberante esercizio di creazione di spazi di dignità da condividere con chi ne è escluso o espulso, senza soluzione di continuità tra quanto è richiesto dalla concretezza quotidiana del luogo in cui si vive, e le priorità imposte dalle infinite diversità degli scenari global

The GISSI Story (1983–1996): A Comprehensive Review

n/

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

n/

949-97 The Prognostic Significance of Systolic and Diastolic Blood Pressure in the Elderly. Suggestions of a 10 Year Follow-up Study

Nowadays the studies evaluating the relationship between blood pressure and (total and cardiovascular) mortality in the elderly have provided conflicting results.Aim of the study was to evaluate the prognostic significance of systolic (SBP) and diastolic (DBP) blood pressure values in a cohort of 3858 elderly outpatients (mean age 72.7±4.9 years, range 65–96 years, 43.5% males) enrolled in the “Study on blood pressure in the elderly-SPAA” and followed up for 10 years.The initial assessment included two BP measurements in two visits. 90 subjects (2.3%) were lost to follow-up. There were 1546 (41%) deaths (TD), 698 from cardiovascular disease (CD). The Table shows the odds ratio (95% CI) for TD and CD according to baseline SBP and DBP (mmHg,*reference group) adjusted for main cardiovascular risk factors and diseases.SBP<140140-159160–179≥ 180TD1*1.1 (0.9–1.3)1.3 (0.0-1.6)1.5 (1.1-2.0)CD1*1.2 (0.9-1.6)1.4 (1.0-1.8)2.0 (1.4-3.0)DBP<9090-9495-104≥105TD1*1.1 (0.9-1.3)0.9 (0.7-1.1)1.2 (0.8-1.7)CD1*1.1(0.9-1.4)1.0 (0.8-1.4)1.2 (0.8-1.9)*reference groupIn our elderly population SBP was associated with total and cardiovascular mortality while DBP was not. A similar pattern was present in both sexes, in elderly aged less or more than 75 years and in subjects with or without pre-existing cardiovascular diseases.These data suggest that SBP should be emphasized more than DBP in the diagnosis and treatment of hypertension in the elderly

Inequalities in the Universal Right to Health

Child health inequalities violate children’s rights to optimal wellbeing. Different issues worldwide affect children’s physical and mental health as well as their development, influencing their future as adults. Inequities are avoidable inequalities. Despite improvements in the past two decades, the ambitious goals of global agendas have, for the most part, remained as expectations with regard to childhood rights, social justice, and health equity in practice. The concept of social determinants of health has become part of the common language in certain settings, but this is still too little to improve health in practice on a global scale, particularly for underprivileged subgroups of the community, as children and adolescents often are. Pediatric health professionals and their organizations are also responsible for guaranteeing children’s and adolescents’ right to health and better wellbeing, helping to reduce health inequalities

Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients

OBJECTIVE—We investigated in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with type 2 diabetes. RESEARCH DESIGN AND METHODS—The Primary Prevention Project (PPP) is a randomized, open trial with a two-by-two factorial design aimed to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events in patients with one or more cardiovascular risk factors. The primary end point was a composite end point of cardiovascular death, stroke, or myocardial infarction. A total of 1,031 people with diabetes in the PPP, aged ≥50 years, without a previous cardiovascular event were enrolled by 316 general practitioners and 14 diabetes outpatient clinics. RESULTS—The PPP trial was prematurely stopped (after a median of 3.7 years) by the independent data safety and monitoring board because of a consistent benefit of aspirin compared with the control group in a population of 4,495 patients with one or more major cardiovascular risk factors. In diabetic patients, aspirin treatment was associated with a nonsignificant reduction in the main end point (relative risk [RR] = 0.90, 95% CI 0.50–1.62) and in total cardiovascular events (0.89, 0.62–1.26) and with a nonsignificant increase in cardiovascular deaths (1.23, 0.69–2.19). In nondiabetic subjects, RRs for the main end point, total cardiovascular events, and cardiovascular deaths were 0.59 (0.37–0.94), 0.69 (0.53–0.90), and 0.32 (0.14–0.72), respectively. No significant reduction in any of the end points considered could be found with vitamin E in either diabetic or nondiabetic subjects. CONCLUSIONS—Our data suggest a lower effect of primary prevention of cardiovascular disease (CVD) with low-dose aspirin in diabetic patients as opposed to subjects with other cardiovascular risk factors. If confirmed, these findings might indicate that the antiplatelet effects of aspirin in diabetic patients are overwhelmed by aspirin-insensitive mechanisms of platelet activation and thrombus formation, thus making the balance between benefits and harms of aspirin treatment unfavorable. Further large-scale trials investigating the role of aspirin in the primary prevention of CVD in diabetic patients are urgently needed

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

Objective To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease